2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. - Wikidata - awgldk - TriplyDB

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

http://www.wikidata.org/entity/Q34600796

about

Telbivudine for chronic hepatitis B KASL clinical practice guidelines: management of chronic hepatitis B Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis The Epigenetic Control of Hepatitis B Virus Modulates the Outcome of Infection Genetic variation of hepatitis B virus and its significance for pathogenesis Anti-HBV Drugs: Progress, Unmet Needs, and New Hope Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis Direct acting antivirals for the treatment of chronic viral hepatitis Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B Approved Antiviral Drugs over the Past 50 Years Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis Current and future antiviral drug therapies of hepatitis B chronic infection Antiviral drug resistance: mechanisms and clinical implications Clinicopathological Features of Telbivudine-Associated Myopathy A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options Safety and efficacy of telbivudine for the treatment of chronic hepatitis B Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission Optimization therapy for the treatment of chronic hepatitis B Early hepatitis B viral DNA clearance predicts treatment response at week 96 Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women.Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.Vertical transmission of hepatitis B virus: challenges and solutions Clinical implications of hepatitis B virus mutations: recent advances.Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B.A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B.Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B.Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.A cutting-edge view on the current state of antiviral drug development.Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Antiviral treatment of chronic hepatitis B virus (HBV) infections Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice

P2860

Q24235644-0D2E0D01-85D3-4CDB-A88A-B9D35EB97A53 Q26752475-83E7372A-7EDA-4C5A-A7E5-126AD583342B Q26765932-6616DA54-370B-4C57-8E9C-5CAC9386ED06 Q26771469-525FCBE6-B125-40CD-B8F4-8DDF9EED9555 Q26772348-C73BDCB6-DAFF-4A8D-BA32-EA4C011242E7 Q26782742-8E1A77EB-E3E6-41D3-B022-FEB476BD47EB Q27000080-B8A14844-5C52-465F-93C8-5F18500FC307 Q27016075-8A41BDBD-446B-4F19-9BC4-40AE93C13826 Q27022216-6A48F90E-338A-4661-B252-12EB03A56FD3 Q27030828-03CD9C01-DC57-401A-B7F8-85AA3611BBD4 Q27755387-2EBC9CC7-B140-4206-9632-B30E5E1A509D Q28074863-F85DD740-2CEE-486D-8189-3FB2C0DFA682 Q28084820-562FD962-5054-49BA-AFD3-75E2291ADB00 Q28282376-2FFBCCE7-EE12-4A57-8501-FDCB0CE0CBD9 Q28553983-B34651CD-0DB3-49AC-BB2B-8342A9298913 Q28704122-D5685B1F-D94F-4219-A000-AA8A68FF8575 Q28972486-FC4224FC-97F2-4B81-A428-13528CA659E3 Q30391932-0D3E3BF4-0C51-4DFA-9656-055C9C9357C1 Q30829485-1F61D96C-5F11-427F-B473-5595D6733E56 Q33560668-BFF09E90-79EB-41B9-B083-A461BA7FFAB9 Q33626813-31C83FE5-9D24-4791-9AFB-E2824A5A6327 Q33628420-9833B4AB-2859-42D2-8FA4-E3638239A315 Q33676349-EB1537C5-C3A4-4E1E-9EC8-2F128FF2C31F Q33676594-ACFB4D31-CECE-4749-9440-9BE183888C59 Q33711399-6A153325-7B85-4224-9A42-470EBDB214D9 Q33718958-FE0873D7-D1C7-408C-B2E5-349011699AA0 Q33774099-D94FBCCB-C8A7-4195-BD54-F6B4498ECD27 Q33801311-29F3FBC5-B55F-4A96-BA61-7F9FAC79DE41 Q33801743-9837C381-58F9-4CA6-963F-9C48E058DE11 Q33807256-EFB41DA8-A1BB-438E-BFDF-FFAF068C200E Q33819098-49665856-8CCE-42A9-8EA4-A49A4CB788A9 Q33872988-9EF91D03-AE81-4CBA-B144-C15FCD888669 Q33948393-A6368885-D373-44E2-90FC-5E15839A6165 Q34036018-A530E730-E64D-4CE3-88B8-37FA0BB9EDAA Q34084987-D6B6F07E-9F69-446B-AD3C-294574A77D6D Q34128296-A02C86B1-5E72-4AC7-8844-8930C3CE6FE5 Q34137291-44216A1D-98B9-4BE2-9555-52158B5AC7FB Q34212799-EDAC79CB-EB31-42D6-A503-8A1A97570D1E Q34223779-1AAC8C4B-731D-4DDD-96C4-C7B100F46BCD Q34256062-B0BFD619-1226-4CCD-BFE4-BA367C508256

P2860

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

http://www.wikidata.org/entity/Q34600796

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

2-Year GLOBE trial results: te ...... ents with chronic hepatitis B.

@ast

2-Year GLOBE trial results: te ...... ents with chronic hepatitis B.

@en

2-Year GLOBE trial results: te ...... ents with chronic hepatitis B.

@nl

type

label

2-Year GLOBE trial results: te ...... ents with chronic hepatitis B.

@ast

2-Year GLOBE trial results: te ...... ents with chronic hepatitis B.

@en

2-Year GLOBE trial results: te ...... ents with chronic hepatitis B.

@nl

prefLabel

2-Year GLOBE trial results: te ...... ents with chronic hepatitis B.

@ast

2-Year GLOBE trial results: te ...... ents with chronic hepatitis B.

@en

2-Year GLOBE trial results: te ...... ents with chronic hepatitis B.

@nl

P1433

Q34600796-7DE127F4-CAD9-4D90-B6F5-4D3E22F6E828

P1476

Q34600796-9D714E89-8482-4547-A0C0-08F7296E7E04

P2093

Q34600796-0101D82C-62A7-4826-95CB-D1BAAFF44445

Q34600796-2015324D-4282-46BE-A112-803F7E0D9654

Q34600796-23F44549-1DDC-4F75-A314-CE0C721358D4

Q34600796-2AA4F2ED-B680-4A95-9F63-C2C4F72B6E8E

Q34600796-498927C7-437A-4634-87AC-4CCAAD1E248B

Q34600796-4A57DC6B-C505-4C97-9BFA-5D9AE0BACAE3

Q34600796-530D4ECA-CAF8-4ECB-A67F-292A501DE301

Q34600796-7198AD87-C09D-46F5-92F7-68AEC4FF8BBE

Q34600796-7854566C-24E4-4AD4-BAA0-378B4787C3A3

Q34600796-7F8AA9D0-AC6D-4D40-8366-25E7F3980674

P304

Q34600796-D772EAF4-2219-4331-9D80-7D85FBA6E111

P31

Q34600796-66777506-6A99-4E0B-9686-681451F5BD35

P356

Q34600796-8D96379A-7D84-4093-BC94-DC8622496F1C

P407

Q34600796-24F1AD71-6E5C-43DD-909E-A33B8E776232

P433

Q34600796-D7AEB697-716E-4E96-93A0-155587A8007C

P478

Q34600796-3C1DA58F-064E-499C-94A2-EE035B71B7DD

P50

Q34600796-2e69d8ce-40f4-5c6e-67be-1bc27ce9d166

Q34600796-A14F98DD-5921-45DC-AEE2-6D2DBB9795B4

Q34600796-F0769A2F-59E4-4075-B4A7-AC99DC41F595

P577

Q34600796-E26F3308-1221-4AF3-BFB3-BCF0A7F4C769

P5875

Q34600796-84081914-F5DA-4135-A383-305C2176863C

P698

Q34600796-636AD39F-A170-47AA-9E46-5E978CEE0044

P356

J.GASTRO.2008.10.026

P1433

Gastroenterology

P1476

2-Year GLOBE trial results: te ...... ents with chronic hepatitis B.

@en

P2093

Ching Lung Lai

http://www.w3.org/2001/XMLSchema#string

E Jenny Heathcote

http://www.w3.org/2001/XMLSchema#string

Edward Gane

http://www.w3.org/2001/XMLSchema#string

Efsevia Albanis

http://www.w3.org/2001/XMLSchema#string

GLOBE Study Group

http://www.w3.org/2001/XMLSchema#string

George Papatheodoridis

http://www.w3.org/2001/XMLSchema#string

Junqi Niu

http://www.w3.org/2001/XMLSchema#string

Karin Galil

http://www.w3.org/2001/XMLSchema#string

Michael Manns

http://www.w3.org/2001/XMLSchema#string

Myron J Tong

http://www.w3.org/2001/XMLSchema#string

P304

486-495

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2008.10.026

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

Yilmaz Cakaloglu

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23490926

http://www.w3.org/2001/XMLSchema#string

P698

19027013

http://www.w3.org/2001/XMLSchema#string